bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S11 from St. John's Wort Attenuates Colorectal Carcinogenesis in Mice through Suppression of Inflammatory Signaling
Authors: Manna Soumen K. , Golla Srujana , Golla Jaya Prakash , Tanaka Naoki , Cai Yan , Takahashi Shogo , Krausz Kristopher W. , Matsubara Tsutomu , Korboukh Ilia , Gonzalez Frank J.
Published: April 2023

Supplementary Figure S11: Hematoxylin and Eosin-stained sections of colon from saline injected mice on control (Con/Sal) or St. John's wort-supplemented diet (SJW/Sal) and AOM injected mice on control (Con/AOM) or St. John's wort-supplemented diet (SJW/Sal) in the four week of the short-term study.
Related Article from Boxing Bladder Cancer with COX-2–specific Inhibition
Authors: Kelly John D. , Hall Emma
Published: April 2023

Related Article from Boxing Bladder Cancer with COX-2–specific Inhibition
Supplementary Table S1 from Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non–Small Cell Lung Cancer and Its Potential as a Circulating Biomarker
Authors: Lou Tzu-Fang , Sethuraman Deepa , Dospoy Patrick , Srivastva Pallevi , Kim Hyun Seok , Kim Joongsoo , Ma Xiaotu , Chen Pei-Hsuan , Huffman Kenneth E. , Frink Robin E. , Larsen Jill E. , Lewis Cheryl , Um Sang-Won , Kim Duk-Hwan , Ahn Jung-Mo , DeBerardinis Ralph J. , White Michael A. , Minna John D. , Yoo Hyuntae
Published: April 2023

194 non-redundant compounds detected in HCC4017 or HBEC30KT cells.
Supplementary Figure S2 from Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence
Authors: Hadac Jamie N. , Leystra Alyssa A. , Paul Olson Terrah J. , Maher Molly E. , Payne Susan N. , Yueh Alexander E. , Schwartz Alexander R. , Albrecht Dawn M. , Clipson Linda , Pasch Cheri A. , Matkowskyj Kristina A. , Halberg Richard B. , Deming Dustin A.
Published: April 2023

Recombination of floxed alleles was confirmed by PCR.
Supplemental Figure 3 from Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice
Authors: Saha Achinto , Blando Jorge , Tremmel Lisa , DiGiovanni John
Published: April 2023

Supplemental Figure 3. Effect of MET, RAPA or MET + RAPA on cell cycle, apoptosis and proliferation markers in human PCa cells.
Supplemental Figure S1 from Fenretinide Perturbs Focal Adhesion Kinase in Premalignant and Malignant Human Oral Keratinocytes. Fenretinide's Chemopreventive Mechanisms Include ECM Interactions
Authors: Han Byungdo B. , Li Suyang , Tong Meng , Holpuch Andrew S. , Spinney Richard , Wang Daren , Border Michael B. , Liu Zhongfa , Sarode Sachin , Pei Ping , Schwendeman Steven P. , Mallery Susan R.
Published: April 2023

Supplemental Figure S1. JSCC cell lines contain cytokeratin and vimentin, suggestive of epithelial-to-mesenchymal transition in subpopulations.
Supplementary Figure 3. from Serum Glycans as Risk Markers for Non–Small Cell Lung Cancer
Authors: Ruhaak L. Renee , Stroble Carol , Dai Jianliang , Barnett Matt , Taguchi Ayumu , Goodman Gary E. , Miyamoto Suzanne , Gandara David , Feng Ziding , Lebrilla Carlito B. , Hanash Samir
Published: April 2023

Bar graphs of grouped glycan intensities showing that the sample preparation method at the individual level yields comparable results to a plate-based method.
supplemental figure 2 from Low SFRP1 Expression Correlates with Poor Prognosis and Promotes Cell Invasion by Activating the Wnt/β-Catenin Signaling Pathway in NPC
Authors: Ren Xian-Yue , Zhou Guan-Qun , Jiang Wei , Sun Ying , Xu Ya-Fei , Li Ying-Qin , Tang Xin-Ran , Wen Xin , He Qing-Mei , Yang Xiao-Jing , Liu Na , Ma Jun
Published: April 2023

Supplemental Figure 2. (A)The SFRP1 mRNA and protein expression of NP69 cells transfected with SFRP1 siRNA compared with the original cell lines and the control siRNA-NC; Effects of SFRP1 siRNA on NP69 cell proliferation(B), migration (C and D).
Supplementary Table S3 from Enhanced Antitumor Effects of Novel Intracellular Delivery of an Active Form of Menaquinone-4, Menahydroquinone-4, into Hepatocellular Carcinoma
Authors: Setoguchi Shuichi , Watase Daisuke , Matsunaga Kazuhisa , Matsubara Misa , Kubo Yohei , Kusuda Mariko , Nagata-Akaho Nami , Enjoji Munechika , Nakashima Manabu , Takeshita Morishige , Karube Yoshiharu , Takata Jiro
Published: April 2023

Supplementary Table S3. Effects of MKH-DMG on liver incidence and growth of DCP-positive HCC in a murine spleen-liver metastasis model.
Supplementary Figure S2 from Enhanced Antitumor Effects of Novel Intracellular Delivery of an Active Form of Menaquinone-4, Menahydroquinone-4, into Hepatocellular Carcinoma
Authors: Setoguchi Shuichi , Watase Daisuke , Matsunaga Kazuhisa , Matsubara Misa , Kubo Yohei , Kusuda Mariko , Nagata-Akaho Nami , Enjoji Munechika , Nakashima Manabu , Takeshita Morishige , Karube Yoshiharu , Takata Jiro
Published: April 2023

Supplementary Figure S2. Intracellular MKO and MK-4 levels after 24 h treatment with MKH-DMG or MK-4 in PLC/PRF/5 cells.
Table S2 from Risk Prediction of Cervical Cancer and Precancers by Type-Specific Human Papillomavirus: Evidence from a Population-Based Cohort Study in China
Authors: Dong Li , Hu Shang-Ying , Zhang Qian , Feng Rui-Mei , Zhang Li , Zhao Xue-Lian , Zhang Xun , Qiao You-Lin , Zhao Fang-Hui
Published: April 2023

Cumulative risk of CIN2+ and 95% confidence interval after one positive test of type-specific hrHPV by multiple infections status.
Supplementary Figure Legends from A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women
Authors: Jiao Li , Maity Suman , Coarfa Cristian , Rajapakshe Kimal , Chen Liang , Jin Feng , Putluri Vasanta , Tinker Lesley F. , Mo Qianxing , Chen Fengju , Sen Subrata , Sangi-Hyghpeykar Haleh , El-Serag Hashem B. , Putluri Nagireddy
Published: April 2023

Figure legend for supplemental documents
Supplementary Figure S6 from Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors
Authors: Ye Xiangcang , Wang Rui , Bhattacharya Rajat , Boulbes Delphine R. , Fan Fan , Xia Ling , Adoni Harish , Ajami Nadim J. , Wong Matthew C. , Smith Daniel P. , Petrosino Joseph F. , Venable Susan , Qiao Wei , Baladandayuthapani Veera , Maru Dipen , Ellis Lee M.
Published: April 2023

Migration of HCP1 CRC cells in a Boyden chamber system.
Supplemental Tables 1-3, Supplemental Figure 1 from Chemopreventive and Antitumor Efficacy of Curcumin in a Spontaneously Developing Hen Ovarian Cancer Model
Authors: Sahin Kazim , Orhan Cemal , Tuzcu Mehmet , Sahin Nurhan , Tastan Hakkı , Özercan İbrahim Hanifi , Güler Osman , Kahraman Nermin , Kucuk Omer , Ozpolat Bulent
Published: April 2023

Supplementary Table 1. Composition of the basal diet given to the study hens. Supplementary Table 2. Incidence of serous and mucinous adenocarcinoma in the study animals. Supplementary Table 3. RAS gene family mutation analysis. Supplementary Figure 1. Detection of curcumin in serum of the animals fed with curcumin by HPLC.
Supplementary Figure from Microbes Contribute to Chemopreventive Efficacy, Intestinal Tumorigenesis, and the Metabolome
Authors: Ferrara Carmen R. , Bai Ji Dong K. , McNally Erin M. , Putzel Gregory G. , Zhou Xi Kathy , Wang Hanhan , Lang Alan , Nagle Deborah , Denoya Paula , Krumsiek Jan , Dannenberg Andrew J. , Montrose David C.
Published: April 2023

Supplementary Figure from Microbes Contribute to Chemopreventive Efficacy, Intestinal Tumorigenesis, and the Metabolome
Supplementary Data from Bufalin, a Traditional Chinese Medicine Compound, Prevents Tumor Formation in Two Murine Models of Colorectal Cancer
Authors: Sun Xiao , Ng Tony T.H. , Sham Kathy W.Y. , Zhang Lin , Chan Matthew T.V. , Wu William K.K. , Cheng Christopher H.K.
Published: April 2023

Table S1, Table S2; Figure S1, Figure S2, Figure S3, Figure S4.
Supplementary File 1 from Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds
Authors: Shan Naing Lin , Minden Audrey , Furmanski Philip , Bak Min Ji , Cai Li , Wernyj Roman , Sargsyan Davit , Cheng David , Wu Renyi , Kuo Hsiao-Chen D. , Li Shanyi N. , Fang Mingzhu , Maehr Hubert , Kong Ah-Ng , Suh Nanjoo
Published: April 2023

Excel File 1
Supplemental Figure Legend from STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma
Authors: Peyser Noah D. , Wang Lin , Zeng Yan , Acquafondata Marie , Freilino Maria , Li Hua , Sen Malabika , Gooding William E. , Satake Masanobu , Wang Zhenghe , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Supplemental Figure Legend.
Supplemental Figure 7 from Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
Authors: Lee Kevin J. , Chang Wen-Chi L. , Chen Xi , Valiyaveettil Jacob , Ramirez-Alcantara Veronica , Gavin Elaine , Musiyenko Alla , Madeira da Silva Luciana , Annamdevula Naga S. , Leavesley Silas J. , Ward Antonio , Mattox Tyler , Lindsey Ashley S. , Andrews Joel , Zhu Bing , Wood Charles , Neese Ashleigh , Nguyen Ashley , Berry Kristy , Maxuitenko Yulia , Moyer Mary Pat , Nurmemmedov Elmar , Gorman Greg , Coward Lori , Zhou Gang , Keeton Adam B. , Cooper Harry S. , Clapper Margie L. , Piazza Gary A.
Published: April 2023

AST and ALT activity of male APC+/Min-FCCC mice administered varying doses of ADT 061 in the diet. Enzyme activity was measured in plasma samples. Results are presented as mean {plus minus} SEM.
Supplementary Tables from Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk
Authors: Ranade Anantbhushan , Bhatt Amit , Page Raymond , Limaye Sewanti , Crook Timothy , Akolkar Dadasaheb , Patil Darshana
Published: April 2023

Supplementary Tables 1-4
Supplementary Table 2 from Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas
Authors: Carvalho Beatriz , Diosdado Begoña , Terhaar Sive Droste Jochim S. , Bolijn Anne S. , Komor Malgorzata A. , de Wit Meike , Bosch Linda J.W. , van Burink Myrthe , Dekker Evelien , Kuipers Ernst J. , Coupé Veerle M.H. , van Grieken Nicole C.T. , Fijneman Remond J.A. , Meijer Gerrit A.
Published: April 2023

Prevalence of gains and losses according to histological features
Supplemental Figure 3A from Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
Authors: Lee Kevin J. , Chang Wen-Chi L. , Chen Xi , Valiyaveettil Jacob , Ramirez-Alcantara Veronica , Gavin Elaine , Musiyenko Alla , Madeira da Silva Luciana , Annamdevula Naga S. , Leavesley Silas J. , Ward Antonio , Mattox Tyler , Lindsey Ashley S. , Andrews Joel , Zhu Bing , Wood Charles , Neese Ashleigh , Nguyen Ashley , Berry Kristy , Maxuitenko Yulia , Moyer Mary Pat , Nurmemmedov Elmar , Gorman Greg , Coward Lori , Zhou Gang , Keeton Adam B. , Cooper Harry S. , Clapper Margie L. , Piazza Gary A.
Published: April 2023

NMR of compound 5.
Supplemental Figure 2C from Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
Authors: Lee Kevin J. , Chang Wen-Chi L. , Chen Xi , Valiyaveettil Jacob , Ramirez-Alcantara Veronica , Gavin Elaine , Musiyenko Alla , Madeira da Silva Luciana , Annamdevula Naga S. , Leavesley Silas J. , Ward Antonio , Mattox Tyler , Lindsey Ashley S. , Andrews Joel , Zhu Bing , Wood Charles , Neese Ashleigh , Nguyen Ashley , Berry Kristy , Maxuitenko Yulia , Moyer Mary Pat , Nurmemmedov Elmar , Gorman Greg , Coward Lori , Zhou Gang , Keeton Adam B. , Cooper Harry S. , Clapper Margie L. , Piazza Gary A.
Published: April 2023

HPLC chromatogram of compound 4.
Supplemental Figure 2B from Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
Authors: Lee Kevin J. , Chang Wen-Chi L. , Chen Xi , Valiyaveettil Jacob , Ramirez-Alcantara Veronica , Gavin Elaine , Musiyenko Alla , Madeira da Silva Luciana , Annamdevula Naga S. , Leavesley Silas J. , Ward Antonio , Mattox Tyler , Lindsey Ashley S. , Andrews Joel , Zhu Bing , Wood Charles , Neese Ashleigh , Nguyen Ashley , Berry Kristy , Maxuitenko Yulia , Moyer Mary Pat , Nurmemmedov Elmar , Gorman Greg , Coward Lori , Zhou Gang , Keeton Adam B. , Cooper Harry S. , Clapper Margie L. , Piazza Gary A.
Published: April 2023

Mass spectroscopy of compound 4.
Supplementary Tables 1-5 from Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma
Authors: Kantrowitz Jacob , Sinjab Ansam , Xu Li , McDowell Tina L. , Sivakumar Smruthy , Lang Wenhua , Nunomura-Nakamura Sayuri , Fukuoka Junya , Nemer Georges , Darwiche Nadine , Chami Hassan , Tfayli Arafat , Wistuba Ignacio I. , Scheet Paul , Fujimoto Junya , Spira Avrum E. , Kadara Humam
Published: April 2023

Supplementary Tables Table S1. Early efffcts of NNK exposure on the mouse airway transcriptome. Table S2. Evolutionarily conserved decreased gene expression in the airway following NNK exposure. Table S3. Genes differentially regulated in the mouse airway at the indicated timepoints post NNK exposure. Table S4. Mouse genes downregulated as early as T2 vs T0 and enriched in airways of human smokers with lung cancer relative to cancer-free smokers. Table S5. Pathways analysis of Mouse genes enriched in airways of human smokers with lung cancer and modulated during in vivo lung oncogenesis
Supplemental Figure 2A from Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
Authors: Lee Kevin J. , Chang Wen-Chi L. , Chen Xi , Valiyaveettil Jacob , Ramirez-Alcantara Veronica , Gavin Elaine , Musiyenko Alla , Madeira da Silva Luciana , Annamdevula Naga S. , Leavesley Silas J. , Ward Antonio , Mattox Tyler , Lindsey Ashley S. , Andrews Joel , Zhu Bing , Wood Charles , Neese Ashleigh , Nguyen Ashley , Berry Kristy , Maxuitenko Yulia , Moyer Mary Pat , Nurmemmedov Elmar , Gorman Greg , Coward Lori , Zhou Gang , Keeton Adam B. , Cooper Harry S. , Clapper Margie L. , Piazza Gary A.
Published: April 2023

NMR of compound 4.
Manuscript supplement from Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma
Authors: Kantrowitz Jacob , Sinjab Ansam , Xu Li , McDowell Tina L. , Sivakumar Smruthy , Lang Wenhua , Nunomura-Nakamura Sayuri , Fukuoka Junya , Nemer Georges , Darwiche Nadine , Chami Hassan , Tfayli Arafat , Wistuba Ignacio I. , Scheet Paul , Fujimoto Junya , Spira Avrum E. , Kadara Humam
Published: April 2023

Supplementary Methods and Supplementary Figure Legends
Supplementary Table 1 from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Authors: Thomas Parijatham S. , Patel Anisha B. , Lee J. Jack , Liu Diane D. , Hernandez Mike , Muzzio Miguel , Contreras Alejandro , Sepeda Valerie , Mays Carrie , Weber Diane , Vornik Lana A. , Khan Seema A. , Dimond Eileen , Heckman-Stoddard Brandy M. , Perloff Marjorie , Brown Powel H.
Published: April 2023

Supplementary Table 1: All Adverse Events related to topical 1% bexarotene gel.
Supplemental Figure S5 from Economic Evaluation of Web- versus Telephone-based Interventions to Simultaneously Increase Colorectal and Breast Cancer Screening Among Women
Authors: Huang Danmeng , Lairson David R. , Chung Tong H. , Monahan Patrick O. , Rawl Susan M. , Champion Victoria L.
Published: April 2023

Supplemental Figure S5 shows the similarity of Cost-Effectiveness Acceptability Curves derived from the participant plus payer's perspectives and the payer perspective.
Supplementary Tables from External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank
Authors: Saunders Catherine L. , Kilian Britt , Thompson Deborah J. , McGeoch Luke J. , Griffin Simon J. , Antoniou Antonis C. , Emery Jon D. , Walter Fiona M. , Dennis Joe , Yang Xin , Usher-Smith Juliet A.
Published: April 2023

Supplementary Tables
Supplementary Data from Individual and Joint Associations of Genetic Risk and Healthy Lifestyle Score with Colorectal Neoplasms Among Participants of Screening Colonoscopy
Authors: Erben Vanessa , Carr Prudence R. , Guo Feng , Weigl Korbinian , Hoffmeister Michael , Brenner Hermann
Published: April 2023

Supplementary Table 1 and Supplementary Table 2
Supplementary Material from Diet-Associated Inflammation Modulates Inflammation and WNT Signaling in the Rectal Mucosa, and the Response to Supplementation with Dietary Fiber
Authors: Malcomson Fiona C. , Willis Naomi D. , McCallum Iain , Xie Long , Shivappa Nitin , Wirth Michael D. , Hébert James R. , Kocaadam-Bozkurt Betul , Özturan-Sirin Aycil , Kelly Seamus B. , Bradburn D. Michael , Belshaw Nigel J. , Johnson Ian T. , Mathers John C.
Published: April 2023

Supplementary Tables 1-11
Table S2 from Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
Authors: Lubet Ronald A. , Heckman-Stoddard Brandy M. , Fox Jennifer T. , Moeinpour Fariba , Juliana M. Margaret , Shoemaker Robert H. , Grubbs Clinton J.
Published: April 2023

Effect of agents on cancer incidence and time to first tumor appearance
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Authors: Marzban Maryam , Mohebbi Elham , Haghdoost AliAkbar , Aryaie Mohammad , Zahedi Mohammad Javad , Khazaei Zaher , Gholizade Mohamad , Naghibzadeh-Tahami Ahmad
Published: April 2023

Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Data from Age at Initiation and Frequency of Screening to Prevent Esophageal Squamous Cell Carcinoma in High-risk Regions: an Economic Evaluation
Authors: Wu Bin , Wang Zhenhua , Zhang Qiang
Published: April 2023

Supplementary figures and tables
Supp Fig S3 from Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer
Authors: Dougherty Urszula , Mustafi Reba , Haider Haider I. , Khalil Abdurahman , Souris Jeffrey S. , Joseph Loren , Hart John , Konda Vani J. , Zhang Wei , Pekow Joel , Li Yan Chun , Bissonnette Marc
Published: April 2023

Human AT1 and AT2 in colon cancers and adjacent mucosa
Supp Fig S2 from Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer
Authors: Dougherty Urszula , Mustafi Reba , Haider Haider I. , Khalil Abdurahman , Souris Jeffrey S. , Joseph Loren , Hart John , Konda Vani J. , Zhang Wei , Pekow Joel , Li Yan Chun , Bissonnette Marc
Published: April 2023

Westerns and IHC of Notch Signals
Supplementary Figure 2 from Myeloid Differentiation Factor 88 Signaling in Bone Marrow–Derived Cells Promotes Gastric Tumorigenesis by Generation of Inflammatory Microenvironment
Authors: Maeda Yusuke , Echizen Kanae , Oshima Hiroko , Yu Liang , Sakulsak Natthiya , Hirose Osamu , Yamada Yoichi , Taniguchi Tadatsugu , Jenkins Brendan J. , Saya Hideyuki , Oshima Masanobu
Published: April 2023

Expression levels of MyD88-dependent unregulated genes in the gp130F/F mice.
Supplementary tables from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies
Authors: Warner Erica T. , Hu Rong , Collins Laura C. , Beck Andrew H. , Schnitt Stuart , Rosner Bernard , Eliassen A. Heather , Michels Karin B. , Willett Walter C. , Tamimi Rulla M.
Published: April 2023

Tables 1 and 2 display estimates for height, BMI at age 18 and somatotypes for pre and postmenopausal women. Table 3 contains estimates for triple negative tumors for all four exposures.
Supplementary Fig S1 from Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis
Authors: Huang Kevin M. , Liang Sherry , Yeung Steven , Oiyemhonlan Etuajie , Cleveland Kristan H. , Parsa Cyrus , Orlando Robert , Meyskens Frank L. , Andresen Bradley T. , Huang Ying
Published: April 2023

Supplemental Figure S1. UV lamp emission spectrum. UVP supplied spectrum of the UV bulb #95-0042-08 and #95-0043-13. Spectrum modified to show a fill under the curve and delete values under zero. The range corresponds to the range depicted for carvedilol absorption in Figure 1.
Supplement Figure 2 from A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial
Authors: Aslam Muhammad N. , Bassis Christine M. , Bergin Ingrid L. , Knuver Karsten , Zick Suzanna M. , Sen Ananda , Turgeon D. Kim , Varani James
Published: April 2023

Metabolomic (Bile acids and SCFA) profile of colon biopsies.
Supplement Figure 1 from A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial
Authors: Aslam Muhammad N. , Bassis Christine M. , Bergin Ingrid L. , Knuver Karsten , Zick Suzanna M. , Sen Ananda , Turgeon D. Kim , Varani James
Published: April 2023

Microbial variability - intra- and inter-subject differences.
Supplementary Table 3 from Physical Activity and Long-term Quality of Life among Colorectal Cancer Survivors—A Population-based Prospective Study
Authors: Eyl Ruth Elisa , Koch-Gallenkamp Lena , Jansen Lina , Walter Viola , Carr Prudence R. , Hoffmeister Michael , Chang-Claude Jenny , Brenner Hermann , Arndt Volker
Published: April 2023

Supplementary Table 3
Supplementary Table 1c from Risk Prediction Models for Colorectal Cancer: A Systematic Review
Authors: Usher-Smith Juliet A. , Walter Fiona M. , Emery Jon D. , Win Aung K. , Griffin Simon J.
Published: April 2023

Details of development of models from cross-sectional studies.
Supplementary Table 2 from A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors
Authors: Biller Leah H. , Ukaegbu Chinedu , Dhingra Tara G. , Burke Carol A. , Chertock Yana , Chittenden Anuradha , Church James M. , Koeppe Erika S. , Leach Brandie H. , Levinson Elana , Lim Ramona M. , Lutz Megan , Salo-Mullen Erin , Sheikh Rania , Idos Gregory , Kastrinos Fay , Stoffel Elena , Weiss Jennifer M. , Hall Michael J. , Kalady Matthew F. , Stadler Zsofia K. , Syngal Sapna , Yurgelun Matthew B.
Published: April 2023

Supplementary Table 2 shows individual case-level data (clinical history, genetic testing, secondary cancers)
supplemental Figure 6 from Unconjugated Bilirubin Is a Novel Prognostic Biomarker for Nasopharyngeal Carcinoma and Inhibits Its Metastasis via Antioxidation Activity
Authors: Deng Cheng-Cheng , Xu Miao , Li Jing , Luo Xiao-Lin , Zhu Yu-Jia , Jiang Rou , Zhang Meng-Xia , Lei Jin-Ju , Lian Yi-Fan , Zou Xiong , You Rui , Chen Li-Zhen , Feng Qi-Sheng , Bei Jin-Xin , Chen Ming-Yuan , Zeng Yi-Xin
Published: April 2023

Supplemental Figure 6.10μM H2O2 treatment could recover the ROS levels of NPC cells treated with UCB.
supplemental Figure 2 from Unconjugated Bilirubin Is a Novel Prognostic Biomarker for Nasopharyngeal Carcinoma and Inhibits Its Metastasis via Antioxidation Activity
Authors: Deng Cheng-Cheng , Xu Miao , Li Jing , Luo Xiao-Lin , Zhu Yu-Jia , Jiang Rou , Zhang Meng-Xia , Lei Jin-Ju , Lian Yi-Fan , Zou Xiong , You Rui , Chen Li-Zhen , Feng Qi-Sheng , Bei Jin-Xin , Chen Ming-Yuan , Zeng Yi-Xin
Published: April 2023

Supplemental Figure 2.UCB inhibits the invasion of 5-8F and S26 cells.
Plasma levels of OPN (ng/ml) in HCC Cases and matched Controls. from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population
Authors: Duarte-Salles Talita , Misra Sandeep , Stepien Magdalena , Plymoth Amelie , Muller David , Overvad Kim , Olsen Anja , Tjønneland Anne , Baglietto Laura , Severi Gianluca , Boutron-Ruault Marie-Christine , Turzanski-Fortner Renee , Kaaks Rudolf , Boeing Heiner , Aleksandrova Krasimira , Trichopoulou Antonia , Lagiou Pagona , Bamia Christina , Pala Valeria , Palli Domenico , Mattiello Amalia , Tumino Rosario , Naccarati Alessio , Bueno-de-Mesquita H.B(as). , Peeters Petra H. , Weiderpass Elisabete , Quirós J. Ramón , Agudo Antonio , Sánchez-Cantalejo Emilio , Ardanaz Eva , Gavrila Diana , Dorronsoro Miren , Werner Mårten , Hemmingsson Oskar , Ohlsson Bodil , Sjöberg Klas , Wareham Nicholas J. , Khaw Kay-Tee , Bradbury Kathryn E. , Gunter Marc J. , Cross Amanda J. , Riboli Elio , Jenab Mazda , Hainaut Pierre , Beretta Laura
Published: April 2023

Plasma levels of OPN (ng/ml) in HCC Cases and matched Controls.
Table S1, Table S2, Table S3, Table S4, Table S5, Table S6, Table S7, Table S8, Fig S1, Fig S2, Fig S3 from High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer
Authors: Bannon Sarah A. , Montiel Maria F. , Goldstein Jennifer B. , Dong Wenli , Mork Maureen E. , Borras Ester , Hasanov Merve , Varadhachary Gauri R. , Maitra Anirban , Katz Matthew H. , Feng Lei , Futreal Andrew , Fogelman David R. , Vilar Eduardo , McAllister Florencia
Published: April 2023

Supplementary Table 1. Criteria for Referral of PDAC patients Supplementary Table 2. Comparison patients tested and non-tested patients in the HRC. Supplementary Table 3. Mutation nomenclature and classification Supplementary Table 4. NCCN guidelines for pancreatic cancer testing Supplementary Table 5. Analysis of patients who met NCCN guidelines Supplementary Table 6. Patient from General Cohort Supplementary Table 7. Comparison of General Cohort patients according to mutational status Supplementary Table 8. Comparison of HRC tested by Panel or by Single gene testing. Supplementary Fig 1. Figure depicting percent of tested patients by panel vs. targeted testing with positive pathogenic mutations or VUS results in the young onset HRC. ***p value<0.0001 calculated by Fisher's exact test Supplementary Fig 2. Mutated genes in High Risk (A) and General (B) Cohorts. Supplementary Fig 3. Kaplan-Meier Survival curves for metastatic patients in the HRC based on their mutational status (A) and for all metastatic PDAC patients from HRC vs. those without mutations from GC.
Supplementary Data from Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812)
Authors: Crew Katherine D. , Anderson Garnet L. , Hershman Dawn L. , Terry Mary Beth , Tehranifar Parisa , Lew Danika L. , Yee Monica , Brown Eric A. , Kairouz Sebastien S. , Kuwajerwala Nafisa , Bevers Therese , Doster John E. , Zarwan Corrine , Kruper Laura , Minasian Lori M. , Ford Leslie , Arun Banu , Neuhouser Marian , Goodman Gary E. , Brown Powel H.
Published: April 2023

Table of baseline characteristics of participants evaluable for the primary endpoint
Fig-S2 from Mitotic Spindle Apparatus Abnormalities in Chronic Obstructive Pulmonary Disease Cells: A Potential Pathway to Lung Cancer
Authors: Thaiparambil Jose , Dong Lingyun , Jasso Diana , Huang Jian-An , El-Zein Randa A.
Published: April 2023

Genes in 96 well format
Suppl Fig legends from Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Authors: Zhang Di , Leal Ana S. , Carapellucci Sarah , Zydeck Kayla , Sporn Michael B. , Liby Karen T.
Published: April 2023

figure legends for supplemental figures
Figure S7 from Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Authors: Zhang Di , Leal Ana S. , Carapellucci Sarah , Zydeck Kayla , Sporn Michael B. , Liby Karen T.
Published: April 2023

Suppl Fig 7: Effects of I-BET 762 on T cells in A/J mice.
Figure S5 from Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Authors: Zhang Di , Leal Ana S. , Carapellucci Sarah , Zydeck Kayla , Sporn Michael B. , Liby Karen T.
Published: April 2023

Suppl Fig 5: c-Myc expression in mammary gland or lung tissue after I-BET 762 treatment.
Figure S3 from Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Authors: Zhang Di , Leal Ana S. , Carapellucci Sarah , Zydeck Kayla , Sporn Michael B. , Liby Karen T.
Published: April 2023

Suppl Fig 3: I-BET 762 and the rexinoid LG268 inhibits iNOS.
Figure S2B from Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Authors: Zhang Di , Leal Ana S. , Carapellucci Sarah , Zydeck Kayla , Sporn Michael B. , Liby Karen T.
Published: April 2023

Suppl Fig 2B: Effects of I-BET 762 on immune cells in PyMT mice after 9 weeks of treatment.
Supplementary Table 2 from Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer
Authors: Anderson Chelsea , Nichols Hazel B. , House Melissa , Sandler Dale P.
Published: April 2023

Supplementary Table 2
Supplementary Data S1 from Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia
Authors: Khandelwal Alok R. , Rong Xiaohua , Moore-Medlin Tara , Ekshyyan Oleksandr , Abreo Fleurette , Gu Xin , Nathan Cherie-Ann O.
Published: April 2023

UVB-induced serum FGF-2. Mice were either mock irradiated or exposed to UVB and treated with either vehicle or C3 as indicated in materials and methods. Serum levels of FGF-2 were determined by ELISA. Data represents mean +/- SEM FGF-2 (pg/ml) for n>5 in each group.
Figure S5 from Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer
Authors: Nelson Omar L. , Rosales Rebecca , Turbov Jane M. , Thaete Larry G. , Cline J. Mark , Rodriguez Gustavo C.
Published: April 2023

Figure S5 shows quantification of the average number of FT cross sections in vehicle- and DMPA-treated groups at 8 and 12 weeks of age. B. Estrogen (E2) levels (pg/ml) in vehicle and DMPA mogp-TAg treated mice at 8 and 12 weeks of age.
Figure S4 from Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer
Authors: Nelson Omar L. , Rosales Rebecca , Turbov Jane M. , Thaete Larry G. , Cline J. Mark , Rodriguez Gustavo C.
Published: April 2023

Figure S4 shows the fallopian Tube at 12 weeks following treatments.
Supplementary Table 3 from HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer
Authors: Valle Blanca L. , Rodriguez-Torres Sebastian , Kuhn Elisabetta , Díaz-Montes Teresa , Parrilla-Castellar Edgardo , Lawson Fahcina P. , Folawiyo Oluwasina , Ili-Gangas Carmen , Brebi-Mieville Priscilla , Eshleman James R. , Herman James , Shih Ie-Ming , Sidransky David , Guerrero-Preston Rafael
Published: April 2023

Methylation and mutation associations
Figure S4 from Temporal Efficacy of a Sulforaphane-Based Broccoli Sprout Diet in Prevention of Breast Cancer through Modulation of Epigenetic Mechanisms
Authors: Li Yuanyuan , Buckhaults Phillip , Li Shizhao , Tollefsbol Trygve
Published: April 2023

Expression changes of specific epigenetic-controlled genes by the postnatal early-life or adult-BSp treatment.
Supplementary Figure from δ-Tocotrienol is the Most Potent Vitamin E Form in Inhibiting Prostate Cancer Cell Growth and Inhibits Prostate Carcinogenesis in Ptenp−/− Mice
Authors: Wang Hong , Yan William , Sun Yuhai , Yang Chung S.
Published: April 2023

Supplementary Figure from δ-Tocotrienol is the Most Potent Vitamin E Form in Inhibiting Prostate Cancer Cell Growth and Inhibits Prostate Carcinogenesis in Ptenp−/− Mice
Tables S1 - S4, Figure S1 from Dietary Advanced Glycation End-products (AGE) and Risk of Breast Cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
Authors: Omofuma Omonefe O. , Turner David P. , Peterson Lindsay L. , Merchant Anwar T. , Zhang Jiajia , Steck Susan E.
Published: April 2023

Supplementary Tables S1-S4 and Figure S1
Supplemental Figure 2. Kaplan-Meier survival curves of Fads1 Null mice. from A New Model to Study the Role of Arachidonic Acid in Colon Cancer Pathophysiology
Authors: Fan Yang-Yi , Callaway Evelyn , M. Monk Jennifer , S. Goldsby Jennifer , Yang Peiying , Vincent Logan , S. Chapkin Robert
Published: April 2023

Fads1 Null mice exhibited low viability when fed a basal AA-free (10% SAF) diet. Dietary supplementation with AA (0.1, 0.4, 0.6 and 2.0%, w/w) dose-dependently reversed the Fads1 Null mouse phenotype (n=3-5).
Supplementary Figure Legends from Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non–Small Cell Lung Carcinogenesis
Authors: Zhang Tianshun , Bai Ruihua , Wang Qiushi , Wang Keke , Li Xiang , Liu Kangdong , Ryu Joohyun , Wang Ting , Chang Xiaoyu , Ma Weiya , Bode Ann M. , Xia Qingxin , Song Yongping , Dong Zigang
Published: April 2023

Supplementary Figure Legends
Supplementary Table 1 from Diallyl Disulfide (DADS), a Constituent of Garlic, Inactivates NF-κB and Prevents Colitis-Induced Colorectal Cancer by Inhibiting GSK-3β
Authors: Saud Shakir M. , Li Weidong , Gray Zane , Matter Matthias S. , Colburn Nancy H. , Young Matthew R. , Kim Young S.
Published: April 2023

Composition of AIN-93G diets
Figure S2 from Scutellarin Suppresses Patient-Derived Xenograft Tumor Growth by Directly Targeting AKT in Esophageal Squamous Cell Carcinoma
Authors: Liu Feifei , Zu Xueyin , Xie Xiaomeng , Zhang Yuanyuan , Liu Kangdong , Chen Hanyong , Wang Ting , Bode Ann M. , Dong Zigang , Kim Dong Joon
Published: April 2023

The effect of scutellarin on mouse body weight
Table S1, Table S2, Table S3, Table S4 from Proton Pump Inhibitor Omeprazole Suppresses Carcinogen-induced Colonic Adenoma Progression to Adenocarcinoma in F344 Rat
Authors: Madka Venkateshwar , Kumar Gaurav , Pathuri Gopal , Panneerselvam Janani , Zhang Yuting , Ganta Vishal , Lightfoot Stanley , Lubet Ronald , Suen Chen S. , Steele Vernon E. , Janakiram Naveena B. , Mohammed Altaf , Rao Chinthalapally V.
Published: April 2023

Supplementary Table 1. Effect of oral OME on terminal body weight and various organs. Supplementary Table 2. Analysis of various serum parameters to determine the effect of OME on liver function (AST & ALT), kidney function (BUN & CREA) and mineral absorption (Mg & Ca). Supplementary Table 3. Partial list of significantly altered pathways (TOP 20) identified using Panther Supplementary Table 4. Selected gene related to tumor growth and progression promoting mechanism / pathways with significantly suppressed gene expression in omeprazole 500 ppm rat colon tumors compared to control.
Supplementary Figures S1-S6 from Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models
Authors: Ku Amy T. , Young Adelaide I.J. , Ibrahim Ahmed Atef , Bu Wen , Jiang Weiyu , Lin Meng , Williams Laterrica C. , McCue Bryant Lee , Miles George , Nagi Chandandeep , Behbod Fariba , Li Yi
Published: April 2023

Supplementary Figure S1 show shows biochemical staining on MCF10A-PIK3CAH1047R mammary tumors. Supplementary Figure S2 shows expression of ERα in MCF10A-PIK3CAH1047R mammary tumors. Supplementary Figure S3 shows response of MCF10A-PIK3CAH1047R cells to fulvestrant in vitro and in vivo. Supplementary Figure S4 shows droplet digital PCR (ddPCR) analysis. Supplementary Figure S5 shows tolerance of alpelisib administration in mice. Supplementary Figure S6 shows short term alpelisib does not affect lung or bone metastasis from MCF10A-PIK3CAH1047R mammary tumors.
Supplementary Table S3 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
Authors: Einstein Mark H. , Roden Richard B.S. , Ferrall Louise , Akin Mark , Blomer Allison , Wu T.C. , Chang Yung-Nien
Published: April 2023

Supplementary Table S3 shows Heart rate of study participants at each visit, including immediately pre- and 30 minutes post-vaccination
Supplementary Figure S2 from Simple Prediction Model for Colorectal Serrated Polyps: Development and External Validation Study in U.S. Prospective Cohorts
Authors: Lyu Zhangyan , Hang Dong , He Xiaosheng , Wu Kana , Cao Yin , Rosner Bernard , Chan Andrew T. , Ogino Shuji , Li Ni , Dai Min , Giovannucci Edward L. , Song Mingyang
Published: April 2023

Supplementary Figure S2: The calibration plot of the simple risk prediction model for high-risk serrated polyps (SPs) across deciles of predicted risk, in women and men.
Data from Analysis of DNA Methylation in Bowel Lavage Fluid for Detection of Colorectal Cancer
Authors: Harada Taku , Yamamoto Eiichiro , Yamano Hiro-o , Nojima Masanori , Maruyama Reo , Kumegawa Kohei , Ashida Masami , Yoshikawa Kenjiro , Kimura Tomoaki , Harada Eiji , Takagi Ryo , Tanaka Yoshihito , Aoki Hironori , Nishizono Masayo , Nakaoka Michiko , Tsuyada Akihiro , Niinuma Takeshi , Kai Masahiro , Shimoda Kazuya , Shinomura Yasuhisa , Sugai Tamotsu , Imai Kohzoh , Suzuki Hiromu
Published: April 2023

Abstract
Aberrant DNA methylation could potentially serve as a biomarker for colorectal neoplasms. In this study, we assessed the feasibility of using DNA methylation detected in bowel lavage fluid (BLF) for colorectal cancer screening. A total of 508 BLF specimens were collected from patients with colorectal cancer (n = 56), advanced adenoma (n = 53), minor polyp (n = 209), and healthy individuals (n = 190) undergoing colonoscopy. Methylation of 15 genes (miR-1-1, miR-9-1, miR-9-3, miR-34b/c, miR-124-1, miR-124-2, miR-124-3, miR-137, SFRP1, SFRP2, APC, DKK2, WIF1, LOC386758, and ZNF582) was then analyzed in MethyLight assays, after which receiver operating characteristic (ROC) curves were analyzed to assess the diagnostic performance of BLF methylation. Through analyzing BLF specimens in a training set (n = 345), we selected the three genes showing the greatest sensitivity for colorectal cancer detection (miR-124-3, 71.8%; LOC386758, 79.5%; and SFRP1, 74.4%). A scoring system based on the methylation of those three genes (M-score) achieved 82% sensitivity and 79% specificity, and the area under the ROC curve (AUC) was 0.834. The strong performance of this system was then validated in an independent test set (n = 153; AUC = 0.808). No significant correlation was found between M-score and the clinicopathologic features of the colorectal cancers. Our results demonstrate that DNA methylation in BLF specimens may be a useful biomarker for the detection of colorectal cancer. Cancer Prev Res; 7(10); 1002–10. ©2014 AACR.
Data from Phase 0 Trials: Expediting the Development of Chemoprevention Agents
Authors: Kummar Shivaani , Doroshow James H.
Published: April 2023

Abstract
Phase 0 trials are first-in-human clinical trials performed under the Exploratory IND [investigational new drug] Guidance of the U.S. Food and Drug Administration. Unlike traditional phase I trials, these studies have no therapeutic or diagnostic intent but instead aim to provide only pharmacokinetic and/or pharmacodynamic data to inform the next step in developing an agent. We discuss the role that such trials, including one reported by Reid and colleagues (beginning on page 347 in this issue of the journal), can play in expanding the number of drugs that are evaluated for chemoprevention while compressing the drug-development timeline. Cancer Prev Res; 4(3); 288–92. ©2011 AACR.
Data from Molecular Imaging of Inflammation and Carcinogenesis
Authors: Ostrov David A. , Contag Christopher H.
Published: April 2023

Abstract
Development of imaging agents that can be used broadly for early detection of neoplasia at various tissue sites and at various stages of disease and that also can assess states of minimal residual disease would have tremendous utility in the diagnosis and management of cancer. In a series of articles culminating with a report in this issue of the journal (beginning on page 1536), Uddin and colleagues show their ability to systemically target the enzyme COX-2 with imaging probes that will serve as agents for early detection, risk assessment, prognosis, and intervention outcome measures. These probes will enable the detection and localization of regions of inflammation and a wide variety of premalignant lesions and cancers, with utility in monitoring the effects of cancer prevention and therapy. Cancer Prev Res; 4(10); 1523–6. ©2011 AACR.
Data from Cancer Prevention Research in China
Authors: Yu Siwang , Yang Chung S. , Li Junyao , You Weicheng , Chen Jianguo , Cao Ya , Dong Zigang , Qiao Youlin
Published: April 2023

Abstract
Although cancer incidence and mortality rates in the United States and some European countries have started to decrease, those in developing countries are increasing. China, the most populous developing country, is facing a serious challenge from cancer. Cancer incidence has been increasing for decades, and cancer is the leading cause of death in China. In 2012, the cancer incidence was 174.0 per 100,000, and the cancer mortality was 122.2 per 100,000 in China. In addition to the still-prevalent traditional Chinese cancers of the stomach, liver, esophagus, cervix, and nasopharynx, the incidence of “Western” cancers such those of the lung, breast, and colorectum has increased alarmingly in recent years. These increases are likely due to the lifestyle and environmental changes associated with rapid economic development and population aging. More importantly, a large portion of these cancers are preventable. Researchers in China have made important contributions to cancer prevention research, especially in the traditional Chinese cancers. More cancer prevention research and measures, especially on the major emerging cancers, are urgently needed. This review article highlights some of the past achievements and present needs in cancer prevention research in China and suggests important areas for future studies. Cancer Prev Res; 8(8); 662–74. ©2015 AACR.
Data from Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence
Authors: Hadac Jamie N. , Leystra Alyssa A. , Paul Olson Terrah J. , Maher Molly E. , Payne Susan N. , Yueh Alexander E. , Schwartz Alexander R. , Albrecht Dawn M. , Clipson Linda , Pasch Cheri A. , Matkowskyj Kristina A. , Halberg Richard B. , Deming Dustin A.
Published: April 2023

Abstract
Human colorectal cancers often possess multiple mutations, including three to six driver mutations per tumor. The timing of when these mutations occur during tumor development and progression continues to be debated. More advanced lesions carry a greater number of driver mutations, indicating that colon tumors might progress from adenomas to carcinomas through the stepwise accumulation of mutations following tumor initiation. However, mutations that have been implicated in tumor progression have been identified in normal-appearing epithelial cells of the colon, leaving the possibility that these mutations might be present before the initiation of tumorigenesis. We utilized mouse models of colon cancer to investigate whether tumorigenesis still occurs through the adenoma-to-carcinoma sequence when multiple mutations are present at the time of tumor initiation. To create a model in which tumors could concomitantly possess mutations in Apc, Kras, and Pik3ca, we developed a novel minimally invasive technique to administer an adenovirus expressing Cre recombinase to a focal region of the colon. Here, we demonstrate that the presence of these additional driver mutations at the time of tumor initiation results in increased tumor multiplicity and an increased rate of progression to invasive adenocarcinomas. These cancers can even metastasize to retroperitoneal lymph nodes or the liver. However, despite having as many as three concomitant driver mutations at the time of initiation, these tumors still proceed through the adenoma-to-carcinoma sequence. Cancer Prev Res; 8(10); 952–61. ©2015 AACR.
Data from The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma
Authors: Wang Mengjun , Devarajan Karthik , Singal Amit G. , Marrero Jorge A. , Dai Jianliang , Feng Ziding , Rinaudo Jo Ann S. , Srivastava Sudhir , Evans Alison , Hann Hie-Won , Lai Yinzhi , Yang Hushan , Block Timothy M. , Mehta Anand
Published: April 2023

Abstract
Biomarkers for the early diagnosis of hepatocellular carcinoma (HCC) are needed to decrease mortality from this cancer. However, as new biomarkers have been slow to be brought to clinical practice, we have developed a diagnostic algorithm that utilizes commonly used clinical measurements in those at risk of developing HCC. Briefly, as α-fetoprotein (AFP) is routinely used, an algorithm that incorporated AFP values along with four other clinical factors was developed. Discovery analysis was performed on electronic data from patients who had liver disease (cirrhosis) alone or HCC in the background of cirrhosis. The discovery set consisted of 360 patients from two independent locations. A logistic regression algorithm was developed that incorporated log-transformed AFP values with age, gender, alkaline phosphatase, and alanine aminotransferase levels. We define this as the Doylestown algorithm. In the discovery set, the Doylestown algorithm improved the overall performance of AFP by 10%. In subsequent external validation in over 2,700 patients from three independent sites, the Doylestown algorithm improved detection of HCC as compared with AFP alone by 4% to 20%. In addition, at a fixed specificity of 95%, the Doylestown algorithm improved the detection of HCC as compared with AFP alone by 2% to 20%. In conclusion, the Doylestown algorithm consolidates clinical laboratory values, with age and gender, which are each individually associated with HCC risk, into a single value that can be used for HCC risk assessment. As such, it should be applicable and useful to the medical community that manages those at risk for developing HCC. Cancer Prev Res; 9(2); 172–9. ©2015 AACR.
Data from CXCR4 Is a Novel Target of Cancer Chemopreventative Isothiocyanates in Prostate Cancer Cells
Authors: Sakao Kozue , Vyas Avani R. , Chinni Sreenivasa R. , Amjad Ali I. , Parikh Rahul , Singh Shivendra V.
Published: April 2023

Abstract
Isothiocyanates (ITCs) derived from cruciferous vegetables, including phenethyl isothiocyanate (PEITC) and sulforaphane (SFN), exhibit in vivo activity against prostate cancer in a xenograft and transgenic mouse model, and thus are appealing for chemoprevention of this disease. Watercress constituent PEITC and SFN-rich broccoli sprout extract are under clinical investigations but the molecular mechanisms underlying their cancer chemopreventive effects are not fully understood. The present study demonstrates that chemokine receptor CXCR4 is a novel target of ITCs in prostate cancer cells. Exposure of prostate cancer cells (LNCaP, 22Rv1, C4-2, and PC-3) to pharmacologically applicable concentrations of PEITC, benzyl isothiocyanate (BITC), and SFN (2.5 and 5 μmol/L) resulted in downregulation of CXCR4 expression. None of the ITCs affected secretion of CXCR4 ligand (stromal-derived factor-1). In vivo inhibition of PC-3 xenograft growth upon PEITC treatment was associated with a significant decrease in CXCR4 protein level. A similar trend was discernible in the tumors from SFN-treated TRAMP mice compared with those of control mice, but the difference was not significant. Stable overexpression of CXCR4 in PC-3 cells conferred significant protection against wound healing, cell migration, and cell viability inhibition by ITCs. Inhibition of cell migration resulting from PEITC and BITC exposure was significantly augmented by RNAi of CXCR4. This study demonstrates, for the first time, that cancer chemopreventive ITCs suppress CXCR4 expression in prostate cancer cells in vitro as well as in vivo. These results suggest that CXCR4 downregulation may be an important pharmacodynamic biomarker of cancer chemopreventative ITCs in prostate adenocarcinoma. Cancer Prev Res; 8(5); 365–74. ©2015 AACR.